Literature DB >> 8816385

Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach.

Y L Colson1, H Li, S S Boggs, K D Patrene, P C Johnson, S T Ildstad.   

Abstract

For over 40 years, the association between hemopoietic chimerism and donor-specific tolerance for allografts has been recognized. However, toxicity associated with lethal conditioning has prevented the clinical application of bone marrow (BM) chimerism to induce tolerance. We previously demonstrated that engraftment could be achieved with less than total recipient myeloablation (700 cGy) and that the incidence of engraftment correlated with the dose of total body irradiation (TBI). Administration of cyclophosphamide (CyP) on Day +2 reduced the minimum TBI dose sufficient to permit engraftment to 500 cGy. In the current study, addition of antilymphocyte globulin (ALG) to the TBI/CyP-based conditioning approach reduced the radiation required for engraftment to < or = 300 cGy. B10 (H-2b) mice conditioned with ALG on day -3, 300 cGy of TBI with transplantation of B10.BR (H-2k) or BALB/c (H-2d) BM on day 0, and CyP on day +2 exhibited evidence of donor chimerism (49.6 +/- 3.7% and 38.2 +/- 2.4%, respectively) in 97% of recipients. ALG eliminated CD4+ and CD8+ cells and decreased NK1.1+ cells in the peripheral circulation at the time of transplantation. Moreover, T and NK cells in the host BM were significantly decreased compared with cells of recipients conditioned with TBI alone. CyP delayed repopulation of host thymocytes, providing time for the establishment of donor chimerism before production of mature T cells. Chimeric animals exhibited stable multilineage chimerism and donor-specific tolerance to skin grafts and in in vitro assays. This model may provide a clinically acceptable approach for the induction of donor-specific transplantation tolerance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816385

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Sensitization to minor antigens is a significant barrier in bone marrow transplantation and is prevented by CD154:CD40 blockade.

Authors:  H Xu; Y Huang; L R Hussain; Z Zhu; L D Bozulic; C Ding; J Yan; S T Ildstad
Journal:  Am J Transplant       Date:  2010-07       Impact factor: 8.086

2.  Simultaneous bone marrow and intestine transplantation promotes marrow-derived hematopoietic stem cell engraftment and chimerism.

Authors:  Atsunori Nakao; Hideyoshi Toyokawa; Kei Kimizuka; Michael A Nalesnik; Isao Nozaki; Robert J Bailey; Anthony J Demetris; Thomas E Starzl; Noriko Murase
Journal:  Blood       Date:  2006-04-25       Impact factor: 22.113

3.  Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients.

Authors:  Hong Xu; Paula M Chilton; Michael K Tanner; Yiming Huang; Carrie L Schanie; Mariano Dy-Liacco; Jun Yan; Suzanne T Ildstad
Journal:  Blood       Date:  2006-08-03       Impact factor: 22.113

Review 4.  The unfinished legacy of liver transplantation: emphasis on immunology.

Authors:  Thomas E Starzl; Fadi G Lakkis
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

Review 5.  Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.

Authors:  H J Symons; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-08-04       Impact factor: 5.483

6.  Fas determines differential fates of resident and recruited macrophages during resolution of acute lung injury.

Authors:  William J Janssen; Lea Barthel; Alaina Muldrow; Rebecca E Oberley-Deegan; Mark T Kearns; Claudia Jakubzick; Peter M Henson
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

7.  In situ macrophage phenotypic transition is affected by altered cellular composition prior to acute sterile muscle injury.

Authors:  Andreas Patsalos; Attila Pap; Tamas Varga; Gyorgy Trencsenyi; Gerardo Alvarado Contreras; Ildiko Garai; Zoltan Papp; Balazs Dezso; Eva Pintye; Laszlo Nagy
Journal:  J Physiol       Date:  2017-08-08       Impact factor: 5.182

Review 8.  HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide.

Authors:  E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

9.  Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model.

Authors:  C A Huang; Y Fuchimoto; R Scheier-Dolberg; M C Murphy; D M Neville; D H Sachs
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 10.  Halfway there: the past, present and future of haploidentical transplantation.

Authors:  M Slade; B Fakhri; B N Savani; R Romee
Journal:  Bone Marrow Transplant       Date:  2016-07-25       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.